Show simple item record

dc.contributor.authorCaswell, R J*
dc.contributor.authorPhillips, D*
dc.contributor.authorChaponda, M*
dc.contributor.authorKhoo, S H*
dc.contributor.authorTaylor, G P*
dc.contributor.authorGhanem, M*
dc.contributor.authorPoulton, M*
dc.contributor.authorWelch, J*
dc.contributor.authorGibbons, S*
dc.contributor.authorJackson, V*
dc.contributor.authorLambert, J S*
dc.date.accessioned2011-10-07T14:15:20Z
dc.date.available2011-10-07T14:15:20Z
dc.date.issued2011-01
dc.identifier.citationUtility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. 2011, 22 (1):11-4 Int J STD AIDSen
dc.identifier.issn1758-1052
dc.identifier.pmid21364060
dc.identifier.doi10.1258/ijsa.2009.009184
dc.identifier.urihttp://hdl.handle.net/10147/144283
dc.descriptionThe pharmacokinetics of antiretroviral drugs in pregnancy is poorly understood. We reviewed the use of therapeutic drug monitoring (TDM) in clinical settings to document plasma concentrations of lopinavir during pregnancy and investigated how clinicians acted upon TDM results. A retrospective review was carried out of all HIV-infected pregnant women taking boosted lopinavir-based highly active antiretroviral therapy (HAART) at five National Health Service (NHS) centres in the UK between May 2004 and March 2007. Seventy-three women in receipt of lopinavir were identified, of whom 89% had plasma lopinavir concentrations above the suggested minimum recommended for wild-type HIV. Initial TDM results prompted dosage change in 10% and assessment of adherence and/or pharmacist review in 11%. TDM was repeated in 29%. TDM can play an important role in the clinical management of HIV-positive pregnant women, allowing informed dose modification and an alternative measure of adherence.en
dc.description.abstractThe pharmacokinetics of antiretroviral drugs in pregnancy is poorly understood. We reviewed the use of therapeutic drug monitoring (TDM) in clinical settings to document plasma concentrations of lopinavir during pregnancy and investigated how clinicians acted upon TDM results. A retrospective review was carried out of all HIV-infected pregnant women taking boosted lopinavir-based highly active antiretroviral therapy (HAART) at five National Health Service (NHS) centres in the UK between May 2004 and March 2007. Seventy-three women in receipt of lopinavir were identified, of whom 89% had plasma lopinavir concentrations above the suggested minimum recommended for wild-type HIV. Initial TDM results prompted dosage change in 10% and assessment of adherence and/or pharmacist review in 11%. TDM was repeated in 29%. TDM can play an important role in the clinical management of HIV-positive pregnant women, allowing informed dose modification and an alternative measure of adherence.
dc.language.isoenen
dc.relation.urlhttp://ijsa.rsmjournals.com/content/22/1/11.longen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAnti-HIV Agents
dc.subject.meshDrug Monitoring
dc.subject.meshFemale
dc.subject.meshGreat Britain
dc.subject.meshHIV Infections
dc.subject.meshHumans
dc.subject.meshPlasma
dc.subject.meshPregnancy
dc.subject.meshPregnancy Complications, Infectious
dc.subject.meshPyrimidinones
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titleUtility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.en
dc.typeArticleen
dc.contributor.departmentDepartment of GU Medicine and Teaching Primary Care Trust, Coventry PCT, Coventry.en
dc.identifier.journalInternational journal of STD & AIDSen
dc.description.provinceLeinster
html.description.abstractThe pharmacokinetics of antiretroviral drugs in pregnancy is poorly understood. We reviewed the use of therapeutic drug monitoring (TDM) in clinical settings to document plasma concentrations of lopinavir during pregnancy and investigated how clinicians acted upon TDM results. A retrospective review was carried out of all HIV-infected pregnant women taking boosted lopinavir-based highly active antiretroviral therapy (HAART) at five National Health Service (NHS) centres in the UK between May 2004 and March 2007. Seventy-three women in receipt of lopinavir were identified, of whom 89% had plasma lopinavir concentrations above the suggested minimum recommended for wild-type HIV. Initial TDM results prompted dosage change in 10% and assessment of adherence and/or pharmacist review in 11%. TDM was repeated in 29%. TDM can play an important role in the clinical management of HIV-positive pregnant women, allowing informed dose modification and an alternative measure of adherence.


This item appears in the following Collection(s)

Show simple item record